Elicio TherapeuticsELTX
Market Cap: $54.7M
About: Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers. It has developed its cancer vaccine product candidates to target biologically validated tumor mutation drivers using known neoantigens.
Employees: 32
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
250% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 2
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
11% more funds holding
Funds holding: 18 [Q1] → 20 (+2) [Q2]
1.48% more ownership
Funds ownership: 4.83% [Q1] → 6.32% (+1.48%) [Q2]
13% less capital invested
Capital invested by funds: $3.08M [Q1] → $2.68M (-$401K) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Robert Burns 49% 1-year accuracy 66 / 134 met price target | 97%upside $10 | Buy Reiterated | 23 Aug 2024 |
Financial journalist opinion
Based on 3 articles about ELTX published over the past 30 days